Chiron/Ortho Diagnostic Systems
This article was originally published in The Gray Sheet
Executive Summary
Receive FDA product license on June 22 for the Chiron RIBA HCV 2.0 strip immunoblot assay, a supplemental test for the detection of hepatitis C virus. The firms say the assay is intended for use as "an additional, more specific test for specimens found to be reactive in HCV antibody screening procedures." They add that the product is a three-stage test utilizing recombinant HCV antigens that "helps physicians to more accurately diagnose past or present hepatitis C infections" by providing "additional information." The HCV 2.0 is the third HCV testing system to result from the companies' collaboration ("The Gray Sheet" March 16, p. 3). Sales will begin the week of June 28.
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.